Compare Pfizer Inc (PFE) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Health Care Select Sector SPDR Fund — how do they compare? Pfizer Inc trades at $27.72 (market cap $158.56B), while Health Care Select Sector SPDR Fund trades at $168.24 (market cap $43.48B). The key difference: Pfizer Inc is far larger — about 3.6× Health Care Select Sector SPDR Fund's market cap, and Pfizer Inc pays a 6.18% dividend while Health Care Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Health Care Select Sector SPDR Fund for 100 Days on average.
| PFE | XLV | |
|---|---|---|
Market Cap | $158.56B | $43.48B |
Volume | 44,138,282 | 11,121,431 |
Sector | Health | — |
52-Week High | $29.02 | $175.68 |
52-Week Low | $23.67 | $141.95 |
Typical Hold Time | 158 Days | 100 Days |
Enterprise Value | $210.06B | — |
Dividend Yield | 6.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
XLV trades at $168.81, up 1.03% today, with a bullish technical signal driven by moving averages. The ETF holds 61 healthcare stocks from the S&P 500, offering broad sector exposure at a low 0.08% expense ratio. Recent news highlights its defensive appeal amid market volatility and potential Fed rate hikes, with articles comparing it favorably to peers like IBB and PJP on cost and diversification.
Outlook is positive given healthcare's defensive growth profile and XLV's cost efficiency, but risks include political uncertainty from midterm elections and sector-specific volatility from drug trial outcomes. Wall Street sentiment is constructive, with the ETF near key resistance at $170.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
